This study is for patients with stage IV squamous cell non-small cell lung cancer, a type of lung cancer. It aims to find the best dose of an investigational medication when used with usual treatments and to see how well it works. The study involves taking chemotherapy drugs and an investigational medication that may help the immune system fight cancer.

Participants will be split into two groups. Both groups will receive treatments through an IV (intravenous, meaning directly into the vein) every 21 days. The treatment will continue for up to 9 months, followed by further treatments for up to another year, depending on the patient's response. After the treatment, there will be a 12-month follow-up period.

• Ages 18 and older can join.
• Participants need to have certain blood and health criteria met.
• Study lasts up to 2 years with several visits and treatments.

Eligibility includes having specific health criteria and not having certain medical conditions or treatments recently. Speak to your doctor to see if this study is right for you.